Outcome of Tocilizumab Treatment in Febrile Neutropenic Children with Severe Sepsis/Septic Shock in a Single-Center Retrospective Case Series.
Shih-Hsiang ChenTsung-Yen ChangYi-Lun WangEn-Pei LeeJainn-Jim LinYi-Wen HsiaoTang-Her JaingChao-Ping YangIou-Jih HungPublished in: Cancers (2024)
Administration of tocilizumab reduced mortality of severe sepsis/septic shock in children with febrile neutropenia. However, it warrants confirmation with a larger number of patients and a longer follow-up.
Keyphrases
- septic shock
- rheumatoid arthritis
- end stage renal disease
- young adults
- newly diagnosed
- ejection fraction
- chronic kidney disease
- chemotherapy induced
- juvenile idiopathic arthritis
- early onset
- rheumatoid arthritis patients
- urinary tract infection
- cardiovascular events
- systemic lupus erythematosus
- cross sectional
- risk factors
- type diabetes
- cardiovascular disease
- acute kidney injury
- patient reported outcomes
- coronary artery disease